Cargando…

COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic

COVID-19, caused by infection of the novel coronavirus SARS-CoV-2, has caused a pandemic of enormous impact that has challenged healthcare and political system throughout the world. This new health emergency has occurred on top of the usual burden of diseases, including systemic sclerosis, and has l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denton, Christopher P, Campochiaro, Corrado, Bruni, Cosimo, Distler, Oliver, Iagnocco, Annamaria, Matucci Cerinic, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922634/ https://www.ncbi.nlm.nih.gov/pubmed/35382249 http://dx.doi.org/10.1177/2397198320963393

Ejemplares similares

Systemic sclerosis in the time of COVID-19
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2022)

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
por: De Luca, Giacomo, et al.
Publicado: (2021)

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

Patient perception of disease burden in diffuse cutaneous systemic sclerosis
por: Khanna, Dinesh, et al.
Publicado: (2019)

One year later: The case of tocilizumab in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis
por: Distler, Oliver, et al.
Publicado: (2018)

The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress
por: Orlandi, Martina, et al.
Publicado: (2020)

Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review
por: Ross, Laura, et al.
Publicado: (2023)

The Treatment of Lung Involvement in Systemic Sclerosis
por: Ruaro, Barbara, et al.
Publicado: (2021)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Similarities between COVID-19 and systemic sclerosis early vasculopathy: A “viral” challenge for future research in scleroderma
por: Matucci-Cerinic, Marco, et al.
Publicado: (2021)

Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review
por: Petelytska, Liubov, et al.
Publicado: (2023)

Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis–Interstitial Lung Disease: A Systematic Review
por: Landini, Nicholas, et al.
Publicado: (2022)

Registry Evaluation of Digital Ulcers in Systemic Sclerosis
por: Galluccio, Felice, et al.
Publicado: (2010)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

IL-21R mRNA is overexpressed in systemic sclerosis and contributes to the epidermal/dermal cross-talk
por: Distler, O, et al.
Publicado: (2003)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis
por: Farina, Nicola, et al.
Publicado: (2022)

The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?
por: Matucci-Cerinic, Marco, et al.
Publicado: (2017)

The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review
por: Orlandi, Martina, et al.
Publicado: (2022)

Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry
por: Matucci-Cerinic, Marco, et al.
Publicado: (2016)

The Emerging Challenge of Pain in Systemic Sclerosis: Similarity to the Pain Experience Reported by Sjőgren’s Syndrome Patients
por: De Luca, Rossella, et al.
Publicado: (2021)

Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort
por: Allanore, Yannick, et al.
Publicado: (2016)

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry
por: Denton, Christopher P, et al.
Publicado: (2012)

The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?
por: Manetti, Mirko, et al.
Publicado: (2016)

Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario
por: Miniati, Irene, et al.
Publicado: (2009)

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
por: Khanna, Dinesh, et al.
Publicado: (2020)

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
por: Denton, Christopher P, et al.
Publicado: (2011)

Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells
por: Mazzotta, Celestina, et al.
Publicado: (2017)

Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?
por: Bruni, Cosimo, et al.
Publicado: (2018)

Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis
por: Mazzotta, Celestina, et al.
Publicado: (2015)

The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review
por: Bonomi, Francesco, et al.
Publicado: (2022)

Oral Lactobacillus Species in Systemic Sclerosis
por: Melchiorre, Daniela, et al.
Publicado: (2021)

Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis
por: Manetti, Mirko, et al.
Publicado: (2010)

Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis
por: Bruni, Cosimo, et al.
Publicado: (2022)

Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
por: Bargagli, Elena, et al.
Publicado: (2019)

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
por: Adler, Sabine, et al.
Publicado: (2018)

Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates
por: Caforio, Alida Linda Patrizia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_la0plqf4anrl9s27qlgabj85th